Ludwig Enterprises, Inc. announced it has entered the booming artificial intelligence cancer screening market. The company, with its wholly owned subsidiary M-RNA for Life, has enlisted the help of the Director of Data Sciences at Nike Inc., Dr. Kyle Ambert PhD, to develop a cancer diagnostic test based on machine learning artificial intelligence (AI). Noninvasive buccal or cheek cells are easily collected using cotton tip swabs and the cells are analyzed for levels of mRNA biomarkers, a dynamic signal associated with inflammatory diseases, such as cancer.

The mRNA biomarkers uncovered by Ludwig are a sensitive dynamic genetic signal associated with cancer that opens the door for the company to participate in the emerging billion dollar diagnostic cancer screening market. The Company's mRNA for Life?? is a one-of-the-kind noninvasive at-home sceening test.

This test uses cutting edge machine learning artificial intelligence (AI) applied by Dr. Kyle Ambert PhD. Dr. Ambert has extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics. Machine learning, as used by M-RNA for Life, is a statistical technique for fitting models to healthcare data and to 'continually learn and update' by training models with patient data.

Dr. Ambert applied 'supervised learning' to predict association of mRNA genetic biomarkers, in cheek cell samples, to specific types of cancers. Ludwig has filed a provisional patent, titled ?mRNAs differentially expressed in colorectal cancer, breast cancer, and bladder cancer.? By utilizing machine learning artificial intelligence (AI), this breakthrough is able identify specific mRNA gene level signals associated with breast, colorectal, and bladder cancer and may allow early detection.